Fix The Patent Laws

US civil society sends letter to US government in support of patent law reform in South Africa

Posted on | November 9, 2017 | No Comments

On 6 November 2017, a group of US civil society organisations sent a letter urging the US government and industry not to interfere with South Africa’s efforts to promote access to lifesaving medicines. The group wrote they were “gravely concerned that the US government and industry representatives will try to undermine the South African government’s plan to reform patent laws over the next few months.” The letter notes that the draft intellectual property policy is both “consistent with South Africa’s international obligations” and “morally necessary.” It also highlights similar, existing policies in US law. The full text of the letter can be read below.

Patient groups march for access to medicines in South Africa

Posted on | October 24, 2017 | No Comments

Finalise the draft policy and amend laws to save lives, activists tell dti

24-10-2017

PRETORIA – Today, more than 1,000 members of the Fix the Patent Laws Coalition (FTPL) will march to the Department of Trade and Industry (dti) in support of the government’s efforts to fix our patent laws and ensure everyone has access to the medicines they need.

Made up of 36 patient groups and civil society organisations representing people affected by most major diseases in South Africa, the FTPL Coalition will hand over its in-depth submission in support of the draft Intellectual Property Policy, and a new report documenting the dire inaccessibility of many cancer medicines due to patent barriers. The draft policy was released by the dti in August 2017.

The draft policy paves the way for a new, progressive intellectual property regime in South Africa, sixteen years after the signing of the Doha Declaration on Public Health – a critical international agreement confirming countries’ ability to amend their laws to incorporate public health safeguards. Notably, for the first time, the draft policy is clear in its prioritising people’s Constitutionally guaranteed right of access to healthcare services, stating that the final policy must “first and foremost engender the ethos of the South African Constitution”.

“This reform process has been ongoing since 2009. We are encouraged that a final policy and actual changes to the law finally seem to be imminent. We march today to support the steps taken by the dti to protect public health, but also to remind the dti that people’s lives depend on the rapid conclusion of this law reform process. Until the relevant Acts are amended, people will continue to suffer and die in South Africa because they can’t access affordable medicines,” says Claire Waterhouse, Access Campaign Advocacy Adviser for Doctors Without Borders Southern Africa.

Sibongile Tshabalala, Chairperson of the Treatment Action Campaign says: “We march in solidarity with all people who cannot access the medicines they need to give them a chance at life, or to ease their suffering. We have lost comrades and friends simply because they couldn’t access the medicines they needed due to high prices driven by unwarranted patent monopolies.”

The march comes almost a year after the tragic passing of prominent FTPL activist, Tobeka Daki – a mother of two fighting HER2+ breast cancer. Daki could not access the medicine she needed, trastuzumab, due to the exorbitant price tag of almost R500,000 per year charged by pharmaceutical corporation Roche because of a protected patent monopoly.

The cancer medicines report launched today highlights that the case of trastuzumab is not unique. Of the 24 cancer medicines examined in the report, 15 are available in India for less than half of the price offered in the South African private sector.

In the most extreme case, a year’s supply of lenalidomide is priced at R882,000 in South Africa compared to less than R32,000 in India. The report confirms earlier research showing that South Africa grants large numbers of secondary patents on medicines that are often rejected in other countries – a critical factor driving the vast price differences on the same medicines in South Africa and India.

While the new medicines report highlights the serious issues in accessing many cancer treatments as a result of South Africa’s current patent laws, this is only one disease among many facing these problems. People across the country suffering from diseases ranging from HIV and TB, to epilepsy, to mental illness are all affected by similar access problems as a result of patent barriers, and it is the widespread nature of this issue that makes the finalising of patent law reforms all the more urgent.

“Luckily, it seems that the dti has woken up to the fact that it’s time to put people’s health over pharmaceutical corporation profits. The cancer report indicates just how urgent this is, which is why we want to show our support for this draft IP policy. This is South Africa’s opportunity to be a global role model in this area and we are ready to push Parliament next year to make this a reality,” says Salomé Meyer of the Cancer Alliance.

SECTION27’s Umunyana Rugege concludes: “The FTPL submission to the dti highlights areas of encouraging progress while continuing to provide recommendations for improvement, to ensure that a pro-public health policy that advances human rights is finalised.”

——————————————————————————————————————————————

For media enquiries, please contact:

Lotti Rutter | TAC | lotti.rutter@tac.org.za | 072 225 9675

Angela Makamure | Doctors Without Borders (MSF)| 079 872 2950

Notes:

  1. REPORT LAUNCH:

“Exploring patent barriers to cancer treatment access in South Africa: 24 medicine case studies”

The report is available here.

The Cancer Alliance and Fix the Patent Laws today launched a new medicines report that outlines 24 specific cancer medicines that people have struggled to access as a result of patent barriers in South Africa.

  1. SUBMISSION TO DTI:

The submission of the Fix the Patent Laws campaign is available here.

Submissions remain open for any organisation or member of the public to submit their comments on the draft IP policy until November 17 2017. More information can be found at www.dti.gov.za

  1. TIMELINE OF PATENT LAW REFORM IN SOUTH AFRICA:

The timeline is available here.

ABOUT THE FIX THE PATEN LAWS CAMPAIGN:

The Fix the Patent Laws campaign is a joint coalition of 36 patient groups, including: AmaBele Belles’ Project Flamingo, Breast Course 4 Nurses, Breast Health Foundation (BHF),  Cancer Association of South Africa (CANSA), Can-Sir, CanSurvive Cancer Support, Cape Mental Health (CMH), Childhood Cancer Foundation of South Africa (CHOC), DiabetesSA, Doctors without Borders (MSF), EpilepsySA, Hospice Palliative Care Association (HPCA), Igazi Foundation, Lymphoedema Association of South Africa (LAOSA), Look Good Feel Better, Marie Stopes South Africa, Men’s Foundation, National Council Against Smoking, Oncology Nursing Association of SA, Pancreatic Cancer Network of SA, People Living With Cancer (PLWC), Pink Trees for Pauline, Pocket Cancer Support, Rainbows and Smiles, Reach for Recovery, Schizophrenia and Bipolar Disorders Alliance (SABDA), SECTION27, South African Depression and Anxiety Group (SADAG), South African Federation of Mental Health (SAFMH), South African Non-Communicable Diseases Alliance (SANCD Alliance), Stop Stock Outs Project (SSP), The Pink Parasol Project, The Sunflower Fund, Treatment Action Campaign (TAC), Vrede Foundation, and Wings of Hope.

#FixPatentLaw

@FixPatentLaw

www.fixthepatentlaws.org

Submission by University of KwaZulu-Natal-Affiliated Academics on SA Draft Intellectual Property Policy

Posted on | October 23, 2017 | No Comments

The Union for Affordable Cancer Treatment comments on SA’s Draft IP Policy

Posted on | October 10, 2017 | No Comments

UACT-300dpi-300pxOn October 10, 2017, the Union for Affordable Cancer Treatment (UACT) and 22 NGOs working on cancer in South Africa and members of the Cancer Alliance, submitted comments to the South Africa on the Draft South Africa IP Policy.

The text of the submission can be read here and below.


Read more

Patient groups welcome release of Draft Intellectual Property Policy

Posted on | August 14, 2017 | No Comments

JOHANNESBURG, 14th AUGUST 2017 – On 8 August 2017, the Department of Trade and Industry published the Draft Intellectual Property Policy of the Republic of South Africa, Phase I, 2017. The Fix the Patent Laws Campaign (FTPL) welcomes its publication for public comment.

The FTPL, a coalition of 34 patient advocacy groups, welcomes the clear statements concerning the critical importance of advancing the Constitutionally guaranteed right of access to healthcare services. The policy points the way towards ensuring everyone in South Africa can access the medicines they need. As pointed out in the draft policy, South Africa currently grants many poor quality patents that are rejected in both other developing countries and in developed countries such as the United States. The draft policy shows an encouraging awareness that it is ultimately people in need of medicines and the South African economy that pays the price for our free-for-all patent system.

The draft policy states that the final policy must “first and foremost engender the ethos of the South African Constitution” and that a developmental and rights centred approach to IP is “urgently necessary”. We welcome the government’s commitments to cooperate to achieve the advancement of Constitutional rights and developmental goals and to do so urgently. The inter-departmental coordination between key departments, including Trade and Industry (DTI), Health, Economic Development, International Relations and Cooperation, Science and Technology and Higher Education and Training will be critical to achieving these goals as multiple departments are responsible for the legislation in need of reform. The FTPL will hold all government stakeholders to these commitments.

The draft policy identifies public health as a priority on the basis of important public interest considerations. It indicates that the DTI, together with key government departments, intends to address substantively in the immediate term, access to medicines, vaccines and diagnostics and South Africa’s approach to international IP cooperation. This policy and law reform process could thus be an important constitutional measure “to achieve the progressive realisation” of the right to health.

We welcome the DTI’s engagement with the United Nations Secretary General’s High-Level Panel on Access to Medicines report, which makes important recommendations about what states can do to ensure greater access to medicines, particularly through patent law reform.

We thank the DTI for taking account of the submissions made in respect of the IP Consultative Framework and for the substantive detail contained in this draft policy. The FTPL will study the draft policy and make comprehensive comments to assist the DTI and its government partners to implement the reforms in line with their constitutional obligations.

The following are preliminary views on the draft policy:

  1. We support the implementation of a system of substantive search and examination of patent applications in order to ensure compliance with existing law and to ensure that only applications deserving of patent protection are granted. We agree with the proposed incremental approach, which we submit can be achieved by starting with the pharmaceutical sector and by considering outsourcing of the examination of applications for patents.
  1. We support the recommendation to introduce pre- and post-grant opposition procedures in our law. We agree that such procedures are beneficial in that they ensure that the patent examiner has access to relevant information concerning the patent application. Third parties, which could include generic companies and civil society groups, will be able to assist the patent examiner in the decision-making process. We encourage an administratively cost-effective procedure and wide access to information concerning patent applications to enable third parties to intervene. We will make detailed submissions on potential interim procedures to enable such interventions as early as possible.
  1. We welcome the commitment to develop patentability criteria in line with the state’s “constitutional obligations, developmental goals and public policy priorities” as well as the intention to utilise available flexibilities to strike the correct balance between promoting innovation and protecting the rights of IP holders and users (patients). We hope that this stated intention will lead to fewer poor quality or ever-greening patents being granted in South Africa and that instead only true innovations will be rewarded with patent protection.
  1. We support the recommendations to introduce non-judicial, cost effective and expeditious mechanisms to obtain medicines through the issuance of compulsory licences. In this regard, we support the recommendation to remove the requirement that a government department first negotiate terms of a licence before approaching a court to seek a compulsory licence. This is not required by the TRIPS Agreement and should be removed through the necessary amendments to the Patents Act.

Unlike countries like Argentina, Brazil and India, South Africa has to date not taken sufficient advantage of the public health flexibilities available to it in international law in order to promote public health. This draft policy provides an opportunity that should not be squandered. It has taken 20 years of stalled policy processes to get to this point. If South Africa wishes to lead on this issue, as is expressed in the policy, the policy must be finalised with the necessary urgency and draft bills must be published with equal urgency so that the people can directly benefit from greater access to medicines for cancer, tuberculosis, HIV, mental health conditions, hepatitis, epilepsy, and many other diseases.

Many people in South Africa continue to die and suffer because they cannot access the medicines that they need. This policy provides hope to those people. It is now up to government to deliver on this promise by swiftly implementing wide-ranging law reform in line with this policy.

The FTPL will publicly share its submission and its full views on the draft policy. We encourage other stakeholders to publicly state their positions on the proposals in the draft policy. Comments are open for 60 days from the date of publication of the draft policy in the Government Gazette.

 

For more information and interviews please contact:

Angela Makamure

Press Officer (MSF)

Phone: 011 403 4440

Mobile: 084 977 7553

angela.makamure@joburg.msf.org

 

About the Fix the Patent Laws Campaign:

The Fix the Patent Laws is a joint coalition of 34 patient groups, including: Advocates for Breast Cancer,  AmaBele Belles’ Project Flamingo, Breast Course 4 Nurses, Breast Health Foundation, Cancer Alliance, Cancer Association of South Africa (CANSA), Can-Sir, CanSurvive Cancer Support, Cape Mental Health (CMH), Care for Cancer Foundation, Childhood Cancer Foundation of South Africa (CHOC), Community Technology Enablement and Collateral Harnessing (Community TECH), DiabetesSA, Doctors without Borders (MSF), EpilepsySA, Hospice Palliative Care Association (HPCA), Igazi Foundation, Look Good Feel Better, Marie Stopes South Africa, Movember, National Council Against Smoking, Oncology Nursing Association of SA, Pancreatic Cancer Network of SA, People Living With Cancer (PLWC), Pink Trees, Pocket Cancer Support, Reach for Recovery, Schizophrenia and Bipolar Disorders Alliance (SABDA), SECTION27, South African Depression and Anxiety Group (SADAG), South African Federation of Mental Health (SAFMH), South African Non-Communicable Diseases Alliance (SANCD Alliance), South African Oncology Social Workers Forum (SAOSWF), Stop Stock Outs Project (SSP), The Sunflower Fund, Treatment Action Campaign, Vrede Foundation, and Wings of Hope.

 

#FixPatentLaw
@FixPatentLaw
www.fixthepatentlaws.org

Letter to Cabinet Ministers: FTPL requests urgent finalisation of the draft intellectual property policy

Posted on | July 20, 2017 | No Comments

On 7 June 2017, the FTPL coalition sent letters to all government ministers who form part of South Africa’s cabinet asking them to urgently finalise the draft intellectual property policy. The draft policy has been delayed in cabinet for more than 2 months, while people living in South Africa still struggle to access the medicines they need affordably, as a result of existing archaic patent laws. Enough is enough!

An example of the letter sent can be seen below:

Coalition welcomes landmark Competition Commission probe into prices of cancer medicines

Posted on | June 13, 2017 | No Comments

JOHANNESBURG, 13 JUNE 2017: The Fix the Patent Laws coalition welcomes the Competition Commission’s announcement earlier today that they will investigate the pricing of several cancer medicines in South Africa. This is a major victory in our struggle to ensure that all people in South Africa can access the medicines they need to stay healthy and alive.

Earlier this year our coalition launched the Tobeka Daki Campaign for Access to Trastuzumab during a global day of action. The campaign was named after Tobeka Daki – a fearless comrade and cancer activist who died of breast cancer in November 2016. Even though Tobeka’s doctor thought she should be provided trastuzumab, Tobeka could never access the medicine due to its high price – over half a million rand per treatment course in the private sector.

The Competition Commission probe announced today will investigate the price of cancer medicines of three pharmaceutical companies. One of these companies is Roche Holdings AG, which will be investigated for the excessive pricing of trastuzumab (the medicine Tobeka never had the chance to try). The investigation specifically relates to “excessive pricing”, “exclusionary conduct”, and “price discrimination”. While Tobeka was unable to access this medicine, Roche made USD 8.9 billion profit in 2015.

The Commission will also investigate local pharmaceutical company Aspen Pharmacare for alleged “abuse of dominance”. Reports in April this year indicated that the Spanish Markets and Competition Commission initiated anti-trust proceedings against Aspen. In October 2016, Aspen was fined over EUR 5 million by the Italian Competition Authority for having abused its dominant position by increasing prices of four of its anti-cancer medicines by up to 1,500%.

The Commission also initiated an investigation against pharmaceutical company Pfizer Inc. for “suspected excessive pricing of lung cancer medication”.

We are encouraged by the Commission’s undertaking to investigate manufacturers of excessively priced cancer medicines. We will be monitoring the Commission’s progress for the duration of these investigations. We are committed to assisting the Commission in their investigation and to ensure that cancer survivors and people who have lost loved ones to cancer have a place at the table. These investigations give hope that more people living with cancer will in future be able to access the medicines that will give them a chance at life.

______________________________________________________________

For more information and to arrange interviews contact:

Luvo Nelani | nelani@section27.org.za | 079 381 8521

The Fix the Patent Laws coalition was founded in November 2011 by the Treatment Action Campaign (TAC), Doctors without Borders (MSF) and SECTION27. Today the coalition has 34 member organisations – including the Cancer Alliance and its various member groups working on cancer-related issues. The coalition has for several years now called on the Department of Trade and Industry to finalise a policy on intellectual property that would ensure that the right to access healthcare is prioritised over the private interests of pharmaceutical companies – as required by the Constitution of South Africa. You can read more about the campaign at www.FixThePatentLaws.org

In South Africa, the annual price charged by Roche for trastuzumab in the private sector is around USD 38 365 (ZAR 516,700). The few public facilities which can access trastuzumab do so at a lower price of around USD 15 735 (ZAR 211,920) per year. But, health economists have shown that a year’s worth of trastuzumab can be produced and sold for only USD 240, a price that includes a 50% increase above the cost of production for profit.

eNCA Checkpoint documentary explores trastuzumab access challenges

Posted on | March 16, 2017 | No Comments

On 14 March 2017, Checkpoint on eNCA aired a documentary exploring the access challenges faced by women in South Africa seeking trastuzumab – a WHO recommended essential medicine for HER2+ breast cancer. The documentary features the story of Tobeka Daki, in whose memory the Tobeka Daki Campaign for Access to Trastuzumab was launched. Watch the documentary at: http://www.enca.com/media/video/checkpoint-out-of-reach-part-1

 

Tobeka Daki Campaign writes to the UN Human Rights Council on Women’s Day

Posted on | March 8, 2017 | No Comments

This letter was issued by the Tobeka Daki Campaign for Access to Trastuzumab to the Human Rights Council today – on International Women’s Day – as they convene a panel discussion on access to medicines in the context of the right to health. The letter can be accessed here.

——

Dear High Commissioner Zeid Ra’ad Al Hussein,

ACCESS TO MEDICINES IS A BASIC HUMAN RIGHT

We are writing to you from the Tobeka Daki Campaign for Access to Trastuzumab in South Africa on the occasion of International Women’s Day to highlight the gross injustice faced by women across the globe in many low and middle income countries who cannot access lifesaving cancer treatments due to the exorbitant pricing of the pharmaceutical industry.

The Tobeka Daki Campaign launched a month ago on 7th February 2017. The campaign is in loving memory of a fearless activist who lead the struggle to ensure access to breast cancer treatment for women in South Africa. Despite being prescribed trastuzumab, a WHO essential medicine for the treatment of HER2+ breast cancer, Tobeka was never able to access the treatment due to its high cost. In South Africa, the annual price charged by Swiss multinational company Roche in the private sector is around US$ 38,365. The few public facilities which can access trastuzumab do so at a lower price of around US$ 15,735 per year. But, health economists have shown that a year’s worth of trastuzumab can be produced and sold for only US$ 240, a price that includes a 50% increase above the cost of production for profit.

Read more

Global Day of Action Against Roche’s Inhumanity #RocheGreedKills

Posted on | February 7, 2017 | No Comments

 

ACTIVISTS AROUND THE WORLD MARCH #ForTobeka

 – Demonstrations held at Roche & pharma associations in South Africa, Malaysia, UK, France, Zambia, Brazil, US

108 organisations endorse a letter to Roche                              

Tuesday, 7th February 2017 – Swiss multinational company Roche faced global condemnation today from women living with cancer, families of people with cancer, activists, scientists, researchers and health professionals from across the world. They highlighted the immoral and unconscionable tactics employed by Roche across the developed and developing world. Roche’s greed is preventing women from accessing affordable versions of trastuzumab, an essential medicine used in the treatment of breast cancer.

The global day of action was led by women living with cancer in South Africa who gathered outside Roche’s office in Johannesburg demanding justice for Tobeka Daki – a leading cancer activist from South Africa whose own struggle against cancer ended last year.

“In South Africa today, we launched the Tobeka Daki Campaign for Access to Trastuzumab. In loving memory of a fearless activist who lead our struggle to ensure women could get this medicine,” said Salomé Meyer of the Cancer Alliance in South Africa. “Even as the likelihood of her being able to get trastuzumab diminished, Tobeka’s determination to ensure other women could access the medicine only grew stronger.”

Despite being a good candidate for trastuzumab, Tobeka was never able to access the treatment due to its high cost. In South Africa the annual price charged by Roche in the private sector is around US$ 38 365 (ZAR 516,700). The few public facilities which can access trastuzumab do so at a lower price of around US$ 15 735 (ZAR 211,920) per year. But, health economists have shown that a year’s worth of trastuzumab can be produced and sold for only US$ 240, a price that includes a 50% increase above the cost of production for profit.

Roche maintains its high prices in every way possible. Roche holds multiple evergreened patents on trastuzumab in certain countries across the world. In South Africa, for example, multiple patents extend Roche’s monopoly until 2033. In countries where the patents expired or do not exist, Roche is using other means to block potentially more affordable biosimilar versions coming to market.

Read more

keep looking »
  • About the Campaign

    fix the patent laws
    Fix the Patent Laws is a campaign of the Treatment Action Campaign (TAC). TAC is a non-profit organisation that seeks to ensure that every person living with HIV has access to quality, comprehensive prevention and treatment services to live a healthy life. Through this blog we will highlight how amending South Africa’s Patents Act 57 of 1978 will reduce the cost of medicines, improving the health and saving the lives of millions of South Africans.

  • Read the TAC and MSF campaign pamphlet

  • Latest tweets